Annual Report

Overview

The report describes Vicore's 2024 progress in its clinical pipeline, including positive Phase 2a AIR results and initiation of the global Phase 2b ASPIRE trial. It also highlights the Nippon Shinyaku license agreement and financing transactions totaling SEK 882 million. Sustainability developments include becoming a UN Global Compact participant and introducing ESG screening criteria into supply and manufacturing procurement.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 25 March 2025
Language: English
Pages
File size

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services